Goodnough L T, Anderson K C
Washington University School of Medicine, St Louis, MO 63110, USA.
Transfus Sci. 1995 Mar;16(1):45-62. doi: 10.1016/0955-3886(94)00059-s.
Recombinant human growth factors are expected to have a significant impact on the use of allogeneic blood components. For example, subsequent to the approval of recombinant human erythropoietin, blood transfusions in renal dialysis patients declined substantially. Likewise, myeloid growth factors have reduced infections and hospital stay by promoting hematologic recovery after high dose ablative chemotherapy. The high costs of these agents mandate that their use be limited to settings where they are clinically indicated. The use of growth factors may be monitored at medical centers by hospital transfusion committees. This chapter reviews the emerging clinical guidelines for the use of hematopoietic growth factors.
重组人生长因子有望对异体血液成分的使用产生重大影响。例如，重组人促红细胞生成素获批后，肾透析患者的输血次数大幅下降。同样，髓系生长因子通过促进大剂量清髓性化疗后的血液学恢复，减少了感染并缩短了住院时间。这些药物成本高昂，因此其使用应仅限于有临床指征的情况。医院输血委员会可在医疗中心对生长因子的使用进行监测。本章回顾了造血生长因子使用方面新出现的临床指南。
